Drug Profile
VK 0214
Alternative Names: MB-10866; VK 0214Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Metabasis Therapeutics
- Developer Viking Therapeutics
- Class Acetates; Benzene derivatives; Phosphorus compounds; Small molecules
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Adrenoleucodystrophy
Most Recent Events
- 31 Dec 2023 Viking Therapeutics has patents pending for thyroid hormone receptor beta agonists in China, Hong Kong, Mexico, Brazil, Russia, New Zealand, South Africa, Europe, PCT
- 31 Dec 2023 Viking Therapeutics has patents protection for thyroid hormone receptor beta agonists in Japan, South Korea, Australia and USA
- 19 Jul 2022 The US FDA lifts the clinical hold on phase I study of VK 0214 in Adrenoleukodystrophy